12,500 Shares in Qiagen N.V. $QGEN Bought by Groupama Asset Managment

Groupama Asset Managment bought a new position in shares of Qiagen N.V. (NYSE:QGEN) in the 1st quarter, HoldingsChannel.com reports. The firm bought 12,500 shares of the company’s stock, valued at approximately $500,000.

A number of other institutional investors have also added to or reduced their stakes in QGEN. Danske Bank A S purchased a new stake in shares of Qiagen in the 3rd quarter valued at about $36,000. Manchester Capital Management LLC purchased a new position in shares of Qiagen during the fourth quarter worth about $42,000. Global Retirement Partners LLC increased its position in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Qiagen in the third quarter worth approximately $64,000. Finally, Kestra Advisory Services LLC purchased a new stake in Qiagen in the fourth quarter valued at approximately $70,000. 70.00% of the stock is currently owned by institutional investors.

Qiagen Stock Up 0.4%

QGEN opened at $41.56 on Monday. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average price is $38.82 and its 200-day moving average price is $41.84. The company has a market cap of $8.56 billion, a P/E ratio of 21.70, a P/E/G ratio of 4.13 and a beta of 0.64.

Qiagen (NYSE:QGEN) last issued its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The company had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. During the same period in the prior year, the business posted $0.56 EPS. On average, equities analysts expect that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were paid a dividend of $0.35 per share. This represents a dividend yield of 90.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s payout ratio is currently 18.32%.

Analyst Ratings Changes

Several brokerages have issued reports on QGEN. Morgan Stanley upgraded shares of Qiagen from an “overweight” rating to an “overweight” rating and lifted their target price for the company from $40.00 to $42.00 in a research report on Tuesday, June 23rd. Barclays set a $38.00 target price on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price objective on Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Stifel Nicolaus set a $36.00 price objective on Qiagen and gave the company a “hold” rating in a report on Monday, May 18th. Finally, Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Qiagen currently has an average rating of “Hold” and an average target price of $43.34.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.